Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HRS-6209 + letrozole versus dalpiciclib or palbociclib + aromatase inhibitor in previously untreated advanced breast cancer
CTR20263901Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing HRS-6209 + letrozole, palbociclib + anastrozole and dalpiciclib + anastrozole (3 arms). Primary endpoint: Progression-free survival by blinded independent central review. Started Oct 2026; status: active.
02
Drugs
HRS-6209letrozoledalpiciclibpalbociclibanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20263901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263901.